<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719055</url>
  </required_header>
  <id_info>
    <org_study_id>A7007</org_study_id>
    <secondary_id>90876777</secondary_id>
    <nct_id>NCT01719055</nct_id>
  </id_info>
  <brief_title>RELIEF - A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain</brief_title>
  <acronym>RELIEF</acronym>
  <official_title>A Global Registry to Evaluate Long-Term Effectiveness of Neurostimulation Therapy for Pain</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compile characteristics of real-world clinical outcomes for Boston Scientific commercially
      approved neurostimulation systems for pain in routine clinical practice, when used according
      to the applicable Directions for Use

      - and -

      To evaluate the economic value and technical performance of Boston Scientific commercially
      approved neurostimulation systems for pain in routine clinical practice
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a prospective, multi-center, global registry of Boston Scientific
      neurostimulation systems for pain.

      The study treatment will consist of neurostimulation trial therapy with any commercially
      approved Boston Scientific Corporation neurostimulator for pain. Positive trials, subjects
      with a successful trial outcome, may progress to permanent implant of a neurostimulation
      system. Individualization of neurostimulation therapy for pain will be determined according
      to investigator discretion and site routine care, and in accordance with inclusion and
      exclusion criteria.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 19, 2012</start_date>
  <completion_date type="Anticipated">April 2028</completion_date>
  <primary_completion_date type="Anticipated">April 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <other_outcome>
    <measure>Percent pain relief</measure>
    <time_frame>up to 36 months follow up</time_frame>
    <description>Percent pain relief of targeted pain at 6, 12, 24 and 36 months follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent pain relief</measure>
    <time_frame>up to 36 months follow up</time_frame>
    <description>Percent pain relief of low back pain at 6, 12, 24 and 36 months follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Percent pain relief</measure>
    <time_frame>up to 36 months follow up</time_frame>
    <description>Percent pain relief of leg pain at 6, 12, 24 and 36 months follow up</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in QoL</measure>
    <time_frame>up to 36 months follow up</time_frame>
    <description>Change in quality of life as reported by the Subject at 6, 12, 24 and 36 months follow up</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">4800</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Boston Scientific SCS Systems</arm_group_label>
    <description>Subjects permanently implanted with a Boston Scientific neurostimulation systems</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>neurostimulation system</intervention_name>
    <description>Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome</description>
    <arm_group_label>Boston Scientific SCS Systems</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who exhibit an on-label indication for neurostimulation to relieve chronic
        intractable pain, according to the Directions for Use, as applicable in each country or
        region
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Study candidate is scheduled to be trialed, on-label, with a commercially approved
             Boston Scientific neurostimulation system for pain, per local directions for use

          -  Signed a valid, IRB/EC-approved informed consent form

          -  18 years of age or older

        Key Exclusion Criteria:

          -  Contraindicated for Boston Scientific neurostimulation system

          -  Currently diagnosed with cognitive impairment, or exhibits any characteristic, that
             would limit study candidate's ability to assess pain relief or to complete study
             assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Roshini Jain</last_name>
    <role>Study Director</role>
    <affiliation>Boston Scientific Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ann Masuda, M.S.</last_name>
    <phone>(661) 949-4726</phone>
    <email>Ann.Masuda@bsci.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Keesey</last_name>
    <phone>(661) 949-4175</phone>
    <email>diane.keesey@bsci.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Boston Scientific Clinical Research Information Toll Free Number</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <zip>91355</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>855-213-9890</phone>
      <email>BSNClinicalTrials@bsci.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>October 30, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>April 29, 2020</last_update_submitted>
  <last_update_submitted_qc>April 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stimulation</keyword>
  <keyword>implantable</keyword>
  <keyword>pulse generator</keyword>
  <keyword>back pain</keyword>
  <keyword>chronic pain</keyword>
  <keyword>leg pain</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

